54 related articles for article (PubMed ID: 19389135)
1. Ligand-specific dynamics of the androgen receptor at its response element in living cells.
Klokk TI; Kurys P; Elbi C; Nagaich AK; Hendarwanto A; Slagsvold T; Chang CY; Hager GL; Saatcioglu F
Mol Cell Biol; 2007 Mar; 27(5):1823-43. PubMed ID: 17189428
[TBL] [Abstract][Full Text] [Related]
2. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
Comuzzi B; Lambrinidis L; Rogatsch H; Godoy-Tundidor S; Knezevic N; Krhen I; Marekovic Z; Bartsch G; Klocker H; Hobisch A; Culig Z
Am J Pathol; 2003 Jan; 162(1):233-41. PubMed ID: 12507906
[TBL] [Abstract][Full Text] [Related]
3. Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer.
Monge A; Jagla M; Lapouge G; Sasorith S; Cruchant M; Wurtz JM; Jacqmin D; Bergerat JP; Céraline J
Cell Mol Life Sci; 2006 Feb; 63(4):487-97. PubMed ID: 16456618
[TBL] [Abstract][Full Text] [Related]
4. Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore.
Ochiai K; Yonezawa R; Fujii S
ChemMedChem; 2024 Mar; 19(6):e202400040. PubMed ID: 38291942
[TBL] [Abstract][Full Text] [Related]
5. Induction of double-strand breaks with the non-steroidal androgen receptor ligand flutamide in patients on androgen suppression: a study protocol for a randomized, double-blind prospective trial.
Lee E; Coulter J; Mishra A; Caramella-Pereira F; Demarzo A; Rudek M; Hu C; Han M; DeWeese TL; Yegnasubramanian S; Song DY
Trials; 2023 Dec; 24(1):809. PubMed ID: 38104131
[TBL] [Abstract][Full Text] [Related]
6. Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications.
Mora-Rodríguez JM; Sánchez BG; Sebastián-Martín A; Díaz-Yuste A; Sánchez-Chapado M; Palacín AM; Sánchez-Rodríguez C; Bort A; Díaz-Laviada I
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958610
[TBL] [Abstract][Full Text] [Related]
7. Identification of the Additional Mitochondrial Liabilities of 2-Hydroxyflutamide When Compared With its Parent Compound, Flutamide in HepG2 Cells.
Ball AL; Kamalian L; Alfirevic A; Lyon JJ; Chadwick AE
Toxicol Sci; 2016 Oct; 153(2):341-51. PubMed ID: 27413113
[TBL] [Abstract][Full Text] [Related]
8.
Akeel Al-Hussaniy H; S Al-Tameemi Z; Al-Zobaidy MJ
F1000Res; 2022; 11():516. PubMed ID: 38779468
[No Abstract] [Full Text] [Related]
9. Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study.
Zhao JG; Liu JD; Shen PF; Tang X; Sun GX; Zhang XM; Chen JR; Shu KP; Shi M; Zeng H
Asian J Androl; 2018; 20(6):545-550. PubMed ID: 30106011
[TBL] [Abstract][Full Text] [Related]
10. Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.
Suh JH; Chattopadhyay A; Sieglaff DH; Storer Samaniego C; Cox MB; Webb P
PLoS One; 2015; 10(9):e0137103. PubMed ID: 26332122
[TBL] [Abstract][Full Text] [Related]
11. Of mice and men--warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively.
Michiel Sedelaar JP; Dalrymple SS; Isaacs JT
Prostate; 2013 Sep; 73(12):1316-25. PubMed ID: 23775398
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation by flutamide modulates uPAR, MMP-9 expressions, lipid profile, and oxidative stress: amelioration by daidzein.
Lateef A; Khan AQ; Tahir M; Khan R; Rehman MU; Ali F; Hamiza OO; Sultana S
Mol Cell Biochem; 2013 Feb; 374(1-2):49-59. PubMed ID: 23135684
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer.
Perets R; Kaplan T; Stein I; Hidas G; Tayeb S; Avraham E; Ben-Neriah Y; Simon I; Pikarsky E
PLoS One; 2012; 7(10):e46467. PubMed ID: 23056316
[TBL] [Abstract][Full Text] [Related]
14. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone.
Sedelaar JP; Isaacs JT
Prostate; 2009 Dec; 69(16):1724-9. PubMed ID: 19676093
[TBL] [Abstract][Full Text] [Related]
15. Suppression of mutant androgen receptors by flutamide.
Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
[TBL] [Abstract][Full Text] [Related]
16. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
[TBL] [Abstract][Full Text] [Related]
17. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Fenton MA; Shuster TD; Fertig AM; Taplin ME; Kolvenbag G; Bubley GJ; Balk SP
Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptors and the molecular basis for the action of antiadrogens in the ventral prostate.
Tymoczko JL; Liao S
J Reprod Fertil Suppl; 1976 Sep; (24 suppl):147-62. PubMed ID: 794465
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
